Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Legal / IP Policy / Regulatory

US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data

Fineline Cube Mar 7, 2024

The U.S. Senate’s homeland security committee has voted 11-1 in favor of the Prohibiting Foreign...

Company Drug

CARsgen Launches BCMA-Targeted CAR-T Therapy in China with High Price Point

Fineline Cube Mar 7, 2024

China-based CAR-T cell therapy specialist CARsgen Therapeutics Holdings Ltd. (HKG: 2171) has launched its BCMA-targeted...

Company Drug

Xian Janssen’s Tremfya Heads for Priority Review in China for Crohn’s Disease Treatment

Fineline Cube Mar 7, 2024

The Center for Drug Evaluation (CDE) has indicated that Xian Janssen Pharmaceutical’s Tremfya (guselkumab), an...

Company Drug

EMA Reviews J&J’s Darzalex Subcutaneous Formulation for Newly Diagnosed Multiple Myeloma

Fineline Cube Mar 7, 2024

The European Medicines Agency (EMA) has this week received an indication extension filing from Johnson...

Company Drug

Gilead and MSD Report Positive Interim Data for Once-Weekly HIV Treatment in Phase II Trial

Fineline Cube Mar 7, 2024

Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co., Inc., known as MSD (NYSE: MRK),...

Company Deals

Gilead and Merus Form Strategic Oncology Alliance to Develop Trispecific T-Cell Engagers

Fineline Cube Mar 7, 2024

Gilead Sciences Inc., (NASDAQ: GILD), has entered into a strategic partnership with Netherlands-based Merus N.V....

Company Drug

Henlius Biotech’s HER2 Targeting Biosimilar Secures Thai and Philippine Approvals

Fineline Cube Mar 7, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) a leading China-based biotech firm, has announced that its...

Company Deals

Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment

Fineline Cube Mar 7, 2024

Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary...

Company

Sino Medical Sciences Gains Pakistani Nod for SC HONKYTONK and NC ROCKSTAR Catheters

Fineline Cube Mar 6, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a Chinese medical device company, has announced that...

Company Drug

Duality Biologics’ DB-1303 on Track for Breakthrough Designation for HER2+ Endometrial Cancer

Fineline Cube Mar 6, 2024

The Center for Drug Evaluation (CDE) website has indicated that DB-1303, a HER2 targeted antibody...

Company Deals

Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform

Fineline Cube Mar 6, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...

Company Deals Digital

ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine

Fineline Cube Mar 6, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has...

Company

Lundbeck A/S Posts 8.2% YOY Revenue Growth in 2023 with Strong Performance Across Key Therapies

Fineline Cube Mar 6, 2024

Danish pharmaceutical company Lundbeck A/S (FRA: LDBB) has announced its financial results for 2023, highlighting...

Company Drug

Formosa Pharmaceuticals Secures FDA Nod for New Steroidal Eye Drug, Set to Launch via Eyenovia

Fineline Cube Mar 6, 2024

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has received approval from the US Food and Drug Administration...

Company Deals

MGI Tech Lands Eurofins Genomics Deal for T20 Ultra-High Throughput Sequencer in Europe

Fineline Cube Mar 6, 2024

MGI Tech (SHA: 688114), a China-based sequencing company, has announced a significant collaboration with Eurofins...

Company Drug

Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates

Fineline Cube Mar 6, 2024

Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of...

Company Drug

Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study

Fineline Cube Mar 6, 2024

Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...

Company Drug

Sandoz Achieves FDA Milestone with Approval of First US Denosumab Biosimilars

Fineline Cube Mar 6, 2024

The US Food and Drug Administration (FDA) has granted Sandoz (SWX: SDZ), a Switzerland-based pharmaceutical...

Company Drug

Hybio Pharmaceutical Gets FDA Nod for Liraglutide Raw Materials with DMF Adequacy Letter

Fineline Cube Mar 6, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a China-based pharmaceutical company, has announced that it has...

Company Drug

Shanghai RAAS Receives NMPA Approval to Initiate Clinical Trial for Hemophilia Preventive Treatment

Fineline Cube Mar 6, 2024

Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has...

Posts pagination

1 … 340 341 342 … 613

Recent updates

  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
  • Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.